1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Otitis Media - Pipeline Review, H1 2017

Otitis Media - Pipeline Review, H1 2017

  • February 2017
  • -
  • Global Markets Direct
  • -
  • 82 pages

Summary

Table of Contents

Search Inside

Otitis Media - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Otitis Media – Pipeline Review, H1 2017, provides an overview of the Otitis Media (Ear Nose Throat Disorders) pipeline landscape.

Otitis media (OM) is any inflammation of the middle ear, the air-filled space behind the eardrum that contains the tiny vibrating bones of the ear. Symptoms include ear pain, difficulty sleeping, loss of balance, fever, headache and loss of appetite. Risk factors include age, seasonal factors and exposure to tobacco smoke or high levels of air pollution. Treatment includes antibiotics and antipyrine.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Otitis Media – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Otitis Media (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Otitis Media (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Otitis Media and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 2, 4 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Otitis Media (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Otitis Media (Ear Nose Throat Disorders).
- The pipeline guide reviews pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Otitis Media (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Otitis Media (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Otitis Media (Ear Nose Throat Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Otitis Media (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016 ...

Tinnitus - Pipeline Review, H1 2017

Tinnitus - Pipeline Review, H1 2017

  • $ 2000
  • Company report
  • April 2017
  • by Global Markets Direct

Tinnitus - Pipeline Review, H1 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Tinnitus - Pipeline Review, H1 2017, provides an overview of the Tinnitus ...

Meniere Disease - Pipeline Review, H1 2017

Meniere Disease - Pipeline Review, H1 2017

  • $ 2000
  • Company report
  • March 2017
  • by Global Markets Direct

Meniere Disease - Pipeline Review, H1 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Meniere Disease - Pipeline Review, H1 2017, provides an overview ...

Tinnitus - Pipeline Review, H2 2016

September 2016 $ 2000

Download Unlimited Documents from Trusted Public Sources

Otonomy, Inc. - Investor Report, August 2016

  • August 2016
    19 pages
  • Ear Disease  

  • United States  

    North America  

View report >

Company Report, July 2016

  • July 2016
    183 pages
  • Nutrition  

    Infectious Dise...  

  • World  

    United States  

View report >

Healthcare Industry - Company Report, June 2016

  • June 2016
    40 pages
  • Pathology  

    Infectious Dise...  

  • World  

    United States  

View report >

Related Market Segments :

Ear Disease
Anti-Infective
Therapy
Pharmaceutical

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.